...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review
【24h】

Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review

机译：探索Covid-19流行病管理中现有药物的重新施加潜力：批判性评论

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite high morbidity and mortality of ongoing coronavirus disease 2019 (COVID-19) pandemic, no specific therapy has been established till date. Though in vitro studies identified various molecules as possible therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), these findings call for substantiation by human studies. We conducted this review aiming at reporting evidences on therapies used so far globally for management of COVID-19 in clinical settings. We searched electronic databases as PubMed, Google Scholar, EMBASE and extracted 612 possible studies as on May 31, 2020. We included original studies of any epidemiological design done on human COVID-19 patients and measured clinical outcomes. Finally, following removal of duplicates and studies meeting exclusion criteria, we derived 22 studies, of which eight were clinical trials, seven were case reports and case series, and seven were observational studies. The most reported therapies were hydroxychloroquine (HCQ) (eight studies) and lopinavir/ritonavir (four studies). We conclude from the evidence generated so far that interferon combined with antivirals, remdesivir, umifenovir and favipiravir were mostly associated with better clinical outcomes. The therapeutic effect of HCQ was established initially by two clinical trials; one of them showing a reinforcing effect by azithromycin but subsequent studies did not elicit any effectiveness rather increased rate of adverse events was reported. Lopinavir/ritonavir was found beneficial when administered with interferon and ribavirin, but one clinical trial on its sole use proved contrary. As many clinical trials are in process, we expect to get concrete evidences on repurposing of existing drugs based on less biased, high powered studies.
机译：尽管持续的冠状病毒疾病的发病率高，但2019年（Covid-19）大流行，但迄今为止没有确定具体治疗。尽管体外研究确定了各种分子，但对严重急性呼吸综合征冠状病毒2（SARS-COV-2）的可能疗法确定了各种分子，但这些研究结果要求通过人类研究证实。我们进行了这篇审查，旨在报告到目前为止用于管理Covid-19在临床环境中使用的疗法的证据。我们将电子数据库搜索为PubMed，Google Scholar，Embase，并提取612年5月31日提取的612个可能的研究。我们包括对人Covid-19患者的任何流行病学设计的原创研究，并测量临床结果。最后，除了删除重复和研究会议和研究会议，我们衍生出22项研究，其中八项是临床试验，七个是案例报告和案例系列，七项是观察性研究。最多报道的疗法是羟基氯喹（HCQ）（八项研究）和Lopinavir / Ritonavir（四项研究）。我们从迄今为止产生的证据中得出结论，干扰素与抗病毒，Remdesivir，Umifenovir和Favipiravir大多相关的临床结果。 HCQ的治疗效果最初由两项临床试验建立;其中一个表现出阿奇霉素的增强效果，但随后的研究没有引起任何有效性，而是报告不良事件的速度。当用干扰素和利巴韦林施用时，洛诺比尔/蓖麻肽被发现有益，但它唯一使用的一个临床试验证明是相反的。正如许多临床试验所在，我们预计会在根据较少偏见，高通量的研究中重新批准现有药物的具体证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号